Normalization of plasma lipoprotein concentrations in patients with type II hyperlipoproteinemia by combined use of neomycin and niacin

J. M. Hoeg, M. B. Maher, E. Bou, L. A. Zech, Kent R Bailey, R. E. Gregg, D. L. Sprecher, J. K. Susser, A. M. Pikus, H. B. Brewer

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The oral administration of neomycin or niacin as single-drug therapy can significantly lower total and low-density lipoprotein cholesterol concentrations in patients with type II hyperlipoproteinemia. However, in the majority of patients treated with one of these drugs as sole therapy plasma lipid and lipoprotein concentrations do not normalize. The effect of combined neomycin (2 g/day) and niacin (3 g/day) treatment on the plasma lipoprotein concentrations was determined in 25 type II hyperlipoproteinemic patients in a double-blind, randomized, placebo-controlled, crossover clinical trial. Treatment with neomycin was well tolerated by all 25 study patients and significantly reduced total and low-density lipoprotein cholesterol concentrations by 23% and 29%, respectively (p < .05). In contrast to the well-tolerated neomycin regimen, 11 patients (44%) were unable to continue niacin treatment because of adverse side effects. In the 14 patients treated with both neomycin and niacin, niacin further lowered the concentrations of total and low-density lipoprotein cholesterol by 18% and 25%, respectively, and increased high-density lipoprotein cholesterol by 32% (p < .05) compared with that in the patients receiving neomycin plus niacin placebo. Compared with diet-only therapy, combined treatment with neomycin plus niacin reduced the total plasma cholesterol concentration by 36% low-density lipoprotein cholesterol by 45%, and the low-density lipoprotein/high-density lipoprotein ratio by 46% and it increased plasma high-density lipoprotein concentrations by 24% (p < .001). During the study, 80% of all the study patients and 92% of the patients who complied with the combined regimen normalized their total and low-density lipoprotein concentrations. No serious or irreversible adverse side effects were detected during combination neomycin/niacin treatment. These results indicate that the lipoprotein concentrations in a majority of type II hyperlipoproteinemic patients can be safely normalized by either therapy with neomycin only or by combined treatment with neomycin/niacin.

Original languageEnglish (US)
Pages (from-to)1004-1011
Number of pages8
JournalCirculation
Volume70
Issue number6
StatePublished - 1984
Externally publishedYes

Fingerprint

Hyperlipoproteinemia Type II
Neomycin
Niacin
Lipoproteins
LDL Cholesterol
HDL Lipoproteins
Therapeutics
LDL Lipoproteins
Placebos
Diet Therapy
Controlled Clinical Trials
Cross-Over Studies
HDL Cholesterol
Oral Administration
Cholesterol
Lipids
Drug Therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

Hoeg, J. M., Maher, M. B., Bou, E., Zech, L. A., Bailey, K. R., Gregg, R. E., ... Brewer, H. B. (1984). Normalization of plasma lipoprotein concentrations in patients with type II hyperlipoproteinemia by combined use of neomycin and niacin. Circulation, 70(6), 1004-1011.

Normalization of plasma lipoprotein concentrations in patients with type II hyperlipoproteinemia by combined use of neomycin and niacin. / Hoeg, J. M.; Maher, M. B.; Bou, E.; Zech, L. A.; Bailey, Kent R; Gregg, R. E.; Sprecher, D. L.; Susser, J. K.; Pikus, A. M.; Brewer, H. B.

In: Circulation, Vol. 70, No. 6, 1984, p. 1004-1011.

Research output: Contribution to journalArticle

Hoeg, JM, Maher, MB, Bou, E, Zech, LA, Bailey, KR, Gregg, RE, Sprecher, DL, Susser, JK, Pikus, AM & Brewer, HB 1984, 'Normalization of plasma lipoprotein concentrations in patients with type II hyperlipoproteinemia by combined use of neomycin and niacin', Circulation, vol. 70, no. 6, pp. 1004-1011.
Hoeg, J. M. ; Maher, M. B. ; Bou, E. ; Zech, L. A. ; Bailey, Kent R ; Gregg, R. E. ; Sprecher, D. L. ; Susser, J. K. ; Pikus, A. M. ; Brewer, H. B. / Normalization of plasma lipoprotein concentrations in patients with type II hyperlipoproteinemia by combined use of neomycin and niacin. In: Circulation. 1984 ; Vol. 70, No. 6. pp. 1004-1011.
@article{d1a304006eca4213b6c76666626e76dd,
title = "Normalization of plasma lipoprotein concentrations in patients with type II hyperlipoproteinemia by combined use of neomycin and niacin",
abstract = "The oral administration of neomycin or niacin as single-drug therapy can significantly lower total and low-density lipoprotein cholesterol concentrations in patients with type II hyperlipoproteinemia. However, in the majority of patients treated with one of these drugs as sole therapy plasma lipid and lipoprotein concentrations do not normalize. The effect of combined neomycin (2 g/day) and niacin (3 g/day) treatment on the plasma lipoprotein concentrations was determined in 25 type II hyperlipoproteinemic patients in a double-blind, randomized, placebo-controlled, crossover clinical trial. Treatment with neomycin was well tolerated by all 25 study patients and significantly reduced total and low-density lipoprotein cholesterol concentrations by 23{\%} and 29{\%}, respectively (p < .05). In contrast to the well-tolerated neomycin regimen, 11 patients (44{\%}) were unable to continue niacin treatment because of adverse side effects. In the 14 patients treated with both neomycin and niacin, niacin further lowered the concentrations of total and low-density lipoprotein cholesterol by 18{\%} and 25{\%}, respectively, and increased high-density lipoprotein cholesterol by 32{\%} (p < .05) compared with that in the patients receiving neomycin plus niacin placebo. Compared with diet-only therapy, combined treatment with neomycin plus niacin reduced the total plasma cholesterol concentration by 36{\%} low-density lipoprotein cholesterol by 45{\%}, and the low-density lipoprotein/high-density lipoprotein ratio by 46{\%} and it increased plasma high-density lipoprotein concentrations by 24{\%} (p < .001). During the study, 80{\%} of all the study patients and 92{\%} of the patients who complied with the combined regimen normalized their total and low-density lipoprotein concentrations. No serious or irreversible adverse side effects were detected during combination neomycin/niacin treatment. These results indicate that the lipoprotein concentrations in a majority of type II hyperlipoproteinemic patients can be safely normalized by either therapy with neomycin only or by combined treatment with neomycin/niacin.",
author = "Hoeg, {J. M.} and Maher, {M. B.} and E. Bou and Zech, {L. A.} and Bailey, {Kent R} and Gregg, {R. E.} and Sprecher, {D. L.} and Susser, {J. K.} and Pikus, {A. M.} and Brewer, {H. B.}",
year = "1984",
language = "English (US)",
volume = "70",
pages = "1004--1011",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Normalization of plasma lipoprotein concentrations in patients with type II hyperlipoproteinemia by combined use of neomycin and niacin

AU - Hoeg, J. M.

AU - Maher, M. B.

AU - Bou, E.

AU - Zech, L. A.

AU - Bailey, Kent R

AU - Gregg, R. E.

AU - Sprecher, D. L.

AU - Susser, J. K.

AU - Pikus, A. M.

AU - Brewer, H. B.

PY - 1984

Y1 - 1984

N2 - The oral administration of neomycin or niacin as single-drug therapy can significantly lower total and low-density lipoprotein cholesterol concentrations in patients with type II hyperlipoproteinemia. However, in the majority of patients treated with one of these drugs as sole therapy plasma lipid and lipoprotein concentrations do not normalize. The effect of combined neomycin (2 g/day) and niacin (3 g/day) treatment on the plasma lipoprotein concentrations was determined in 25 type II hyperlipoproteinemic patients in a double-blind, randomized, placebo-controlled, crossover clinical trial. Treatment with neomycin was well tolerated by all 25 study patients and significantly reduced total and low-density lipoprotein cholesterol concentrations by 23% and 29%, respectively (p < .05). In contrast to the well-tolerated neomycin regimen, 11 patients (44%) were unable to continue niacin treatment because of adverse side effects. In the 14 patients treated with both neomycin and niacin, niacin further lowered the concentrations of total and low-density lipoprotein cholesterol by 18% and 25%, respectively, and increased high-density lipoprotein cholesterol by 32% (p < .05) compared with that in the patients receiving neomycin plus niacin placebo. Compared with diet-only therapy, combined treatment with neomycin plus niacin reduced the total plasma cholesterol concentration by 36% low-density lipoprotein cholesterol by 45%, and the low-density lipoprotein/high-density lipoprotein ratio by 46% and it increased plasma high-density lipoprotein concentrations by 24% (p < .001). During the study, 80% of all the study patients and 92% of the patients who complied with the combined regimen normalized their total and low-density lipoprotein concentrations. No serious or irreversible adverse side effects were detected during combination neomycin/niacin treatment. These results indicate that the lipoprotein concentrations in a majority of type II hyperlipoproteinemic patients can be safely normalized by either therapy with neomycin only or by combined treatment with neomycin/niacin.

AB - The oral administration of neomycin or niacin as single-drug therapy can significantly lower total and low-density lipoprotein cholesterol concentrations in patients with type II hyperlipoproteinemia. However, in the majority of patients treated with one of these drugs as sole therapy plasma lipid and lipoprotein concentrations do not normalize. The effect of combined neomycin (2 g/day) and niacin (3 g/day) treatment on the plasma lipoprotein concentrations was determined in 25 type II hyperlipoproteinemic patients in a double-blind, randomized, placebo-controlled, crossover clinical trial. Treatment with neomycin was well tolerated by all 25 study patients and significantly reduced total and low-density lipoprotein cholesterol concentrations by 23% and 29%, respectively (p < .05). In contrast to the well-tolerated neomycin regimen, 11 patients (44%) were unable to continue niacin treatment because of adverse side effects. In the 14 patients treated with both neomycin and niacin, niacin further lowered the concentrations of total and low-density lipoprotein cholesterol by 18% and 25%, respectively, and increased high-density lipoprotein cholesterol by 32% (p < .05) compared with that in the patients receiving neomycin plus niacin placebo. Compared with diet-only therapy, combined treatment with neomycin plus niacin reduced the total plasma cholesterol concentration by 36% low-density lipoprotein cholesterol by 45%, and the low-density lipoprotein/high-density lipoprotein ratio by 46% and it increased plasma high-density lipoprotein concentrations by 24% (p < .001). During the study, 80% of all the study patients and 92% of the patients who complied with the combined regimen normalized their total and low-density lipoprotein concentrations. No serious or irreversible adverse side effects were detected during combination neomycin/niacin treatment. These results indicate that the lipoprotein concentrations in a majority of type II hyperlipoproteinemic patients can be safely normalized by either therapy with neomycin only or by combined treatment with neomycin/niacin.

UR - http://www.scopus.com/inward/record.url?scp=0021710116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021710116&partnerID=8YFLogxK

M3 - Article

C2 - 6388897

AN - SCOPUS:0021710116

VL - 70

SP - 1004

EP - 1011

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 6

ER -